Medtronic Unleashes $780 Million Deal Spree After Strong Quarter
Medtronic (NYSE: MDT) stock rose after beating Q1 estimates and raising its FY27 forecast on strong cardiovascular sales.
Medtronic did better than expected this quarter, especially selling heart devices, so the company is now spending $780 million on new stuff. When a company does really well and has confidence to invest, it can mean good things ahead—but markets always change.
Last session drawn · prints held ~15 minutes · licensed exchange data
Source: Benzinga · Read the original report at the publisher. Headline and figures shown for context; data may be delayed.
Disclosure: Educational and informational purposes only — not financial advice. We educate, not advise. Market data may be delayed up to 15 minutes unless marked real-time. Past performance is not indicative of future results.